Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study

NCT07589322 is registered in ClinicalTrials.gov with Tri-Service General Hospital (TSGH) as lead sponsor.

NCT NCT07589322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07589322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
Lead sponsor
Tri-Service General Hospital (TSGH)
Phase
Not applicable
Overall status
Recruiting
Start date
March 31, 2026
Completion date
September 30, 2029
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and metabolic syndrome